Do Oncology Clinical Trial Participants Cost More for Payers?

Multilayered strategies such as working with patient advocacy organizations and leveraging technology can help industry better partner with patients.

The Phase II KRAKEN trial demonstrated that muvalaplin, Eli Lilly's first-in-class oral small molecule inhibitor, significantly reduces lipoprotein(a) levels with minimal adverse effects, offering a promising new approach to addressing a major cardiovascular risk factor.

Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.

This November issue of ACT explores those technological innovations in clinical trial recruitment and data collection and management that are being geared toward empowering the research community's most important asset—the patient.

The Phase III CLEAR SYNERGY trial found that long-term colchicine treatment after acute myocardial infarction does not reduce major cardiovascular events compared to placebo, highlighting mixed results from prior studies on its efficacy in cardiovascular disease.

How the inclusion of measures centered on net treatment benefit can drive an effective multifaceted approach.